Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% chance
$11,414 Vol.
$11,414 Vol.
Oct 6, 2026
13% chance
$11,414 Vol.
$11,414 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,414End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,414End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on applying the SmartDepot microsphere formulation to peptide candidates, including GLP-1 agents and CNS programs. This stage explicitly excludes commercial rights and permits termination on 30 days’ notice, with no public disclosure of a binding licensing, technology transfer, or equivalent commercial deal despite nearly two years of in-vivo validation work. Recent developments, including Lilly’s separate long-acting formulation partnerships and Peptron’s focus on internal pipeline progress and manufacturing expansion, have reinforced trader consensus that a full commercial license is unlikely before the deadline.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions